Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK4 | Q16654 | 1/20 | 0.51 |
| ▸ | GRM5 | P41594 | 10/20 | 0.47 |
| ▸ | GRM1 | Q13255 | 10/20 | 0.46 |
| ▸ | NAMPT | P43490 | 1/20 | 0.45 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.44 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.43 |
| ▸ | HTR6 | P50406 | 1/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.41 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL74898 | 0.80 | PDK4 (0.42) | PDK4GRM5GRM1NAMPTESR2 | |
| SCHEMBL10201181 | 0.80 | PDK4 (0.51) | PDK4GRM5GRM1NAMPTESR2 | |
| SCHEMBL12320441 | 0.80 | PDK4 (0.51) | PDK4GRM5GRM1NAMPTESR2 | |
| SCHEMBL8218881 | 0.80 | PDK4 (0.51) | PDK4GRM5GRM1NAMPTESR2 | |
| SCHEMBL12999429 | 0.79 | GRM5 (0.53) | PDK4GRM5GRM1NAMPTESR2 | |
| SCHEMBL13177723 | 0.78 | ADORA1 (0.51) | PDK4GRM5GRM1NAMPTESR2 | |
| SCHEMBL16936975 | 0.78 | PDK4 (0.50) | PDK4GRM5GRM1NAMPTESR2 | |
| SCHEMBL14028045 | 0.78 | PDK4 (0.50) | PDK4GRM5GRM1NAMPTESR2 | |
| SCHEMBL12069963 | 0.78 | PDK4 (0.50) | PDK4GRM5GRM1NAMPTESR2 | |
| SCHEMBL14301396 | 0.78 | PDK4 (0.50) | PDK4GRM5GRM1NAMPTESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 113 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1954287-B2 | CETP INHIBITORS | MERCK SHARP & DOHME (US) | 2016-02-24 | — | — | EP | disclosed |
| EP-2573079-A2 | Benzimidazole quinolinones and uses thereof | Novartis Vaccines and Diagnostics, Inc. (US) | 2013-03-27 | — | — | EP | disclosed |
| US-8334290-B2 | CETP inhibitors | MERCK SHARP & DOHME CORP. (US) | 2012-12-18 | — | — | US | disclosed |
| EP-1954287-B1 | CETP INHIBITORS | MERCK SHARP & DOHME (US) | 2011-11-16 | — | — | EP | disclosed |
| US-20110262658-A1 | PROCESS AND DEVICE FOR TREATING THE COATING OF THERMOPLASTIC RESIN CONTAINERS | ZOPPAS MATTEO | 2011-10-27 | — | — | US | disclosed |
| US-7825132-B2 | Inhibition of FGFR3 and treatment of multiple myeloma | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2010-11-02 | — | — | US | disclosed |
| US-7700591-B2 | Benzoxazinyl-amidocyclopentyl-heterocyclic modulators of chemokine receptors | MERCK & CO., INC. (US) | 2010-04-20 | — | — | US | disclosed |
| EP-1615699-B1 | BENZOXAZINYL-AMIDOCYCLOPENTYL-HETEROCYCLIC MODULATORS OF CHEMOKINE RECEPTORS | MERCK SHARP & DOHME (US) | 2010-03-24 | — | — | EP | disclosed |
| US-20090281100-A1 | Benzimidazole quinolinones and uses thereof | BARSANTI PAUL A | 2009-11-12 | — | — | US | disclosed |
| US-20090264405-A1 | Cetp Inhibitors | MERCK SHARP & DOHME LLC | 2009-10-22 | — | — | US | disclosed |
| WO-1997036867-A1 | BENZYL(IDENE)-LACTAM DERIVATIVES, THEIR PREPARATION AND THEIR USE AS SELECTIVE (ANT)AGONISTS OF 5-HT1A- AND/OR 5-HT1D RECEPTORS | PFIZER INC. (US) | 1997-10-09 | — | — | WO | disclosed |
| US-5665719-A | Benzoxazinone and benzopyrimidinone piperidinyl tocolytic oxytocin receptor antagonists | MERCK & CO., INC. (US) | 1997-09-09 | — | — | US | disclosed |
| US-5597826-A | Compositions containing sertraline and a 5-HT1D receptor agonist or antagonist | PFIZER INC. (US) | 1997-01-28 | — | — | US | disclosed |
| EP-0714299-A4 | — | — | 1996-07-10 | — | — | EP | disclosed |
| EP-0714299-A1 | BENZOXAZINONE AND BENZOPYRIMIDINONE PIPERIDINYL TOCOLYTIC OXYTOCIN RECEPTOR ANTAGONISTS | MERCK & CO. INC. (US) | 1996-06-05 | — | — | EP | disclosed |
| EP-0701819-A2 | Novel compositions containing sertraline and a 5-HT1D receptor agonist or antagonist | PFIZER INC. (US) | 1996-03-20 | — | — | EP | disclosed |
| EP-0689536-A1 | NAPHTHALENE DERIVATIVES | PFIZER INC. (US) | 1996-01-03 | — | — | EP | disclosed |
| WO-1995002405-A1 | BENZOXAZINONE AND BENZOPYRIMIDINONE PIPERIDINYL TOCOLYTIC OXYTOCIN RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 1995-01-26 | — | — | WO | disclosed |
| WO-1994021619-A1 | NAPHTHALENE DERIVATIVES | PFIZER INC. (US) | 1994-09-29 | — | — | WO | disclosed |
| US-4945160-A | Preparation of certain 7-substituted quinolones | WARNER-LAMBERT COMPANY (US) | 1990-07-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264405-A1 | Cetp Inhibitors | CETP, APOB, PCSK9 | PDK4 3935/4885GRM5 4767/4885GRM1 4844/4885 |
| US-20090281100-A1 | Benzimidazole quinolinones and uses thereof | GAA, ALPI, IL4I1 | PDK4 312/4885GRM5 3586/4885GRM1 3406/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.